Lisata Therapeutics (NASDAQ:LSTA) Cut to “Hold” at Zacks Research

Zacks Research cut shares of Lisata Therapeutics (NASDAQ:LSTA) from a strong-buy rating to a hold rating in a report issued on Monday,Zacks.com reports.

A number of other brokerages have also recently issued reports on LSTA. Brookline Capital Management upped their price objective on shares of Lisata Therapeutics from $20.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a report on Thursday, August 21st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $23.50.

Lisata Therapeutics Stock Performance

Shares of LSTA opened at $2.16 on Monday. The firm has a market cap of $18.91 million, a PE ratio of -0.97 and a beta of 1.01. The firm’s 50 day moving average price is $2.39 and its 200 day moving average price is $2.50. Lisata Therapeutics has a twelve month low of $1.87 and a twelve month high of $4.20.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.05. On average, sell-side analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lisata Therapeutics stock. Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,183 shares of the company’s stock, valued at approximately $32,000. Cerity Partners LLC owned about 0.14% of Lisata Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.